Portola Pharmaceuticals (PTLA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
Average Volume
3.17 million shs
Market Capitalization
$1.42 billion
P/E Ratio
Dividend Yield
Price Target
PTLA stock logo

About Portola Pharmaceuticals Stock (NASDAQ:PTLA)

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

PTLA Stock News Headlines

Portola Middle
Fault lines in Portola Valley
Portola-Butler Continuation High School
Eagle Pharmaceuticals
PTLA_old Historical Data
KPRX Kiora Pharmaceuticals, Inc.
See More Headlines
Receive PTLA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Portola Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings

Industry, Sector and Symbol

Pharmaceutical Preparations
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$116.64 million
Book Value
$1.67 per share


Free Float
Market Cap
$1.42 billion
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Ms. Mardi C. Dier (Age 55)
    Exec. VP, Chief Bus. Officer & CFO
  • Dr. John T. Curnutte (Age 67)
    Exec. VP and Head of R&D
  • Mr. J. Scott Garland M.B.A. (Age 50)
    MBA, Pres & CEO
  • Cara Miller
    VP of Investor Relations and Corp. Communications
  • Mr. John B. Moriarty Jr. (Age 51)
    Exec. VP, Gen. Counsel & Sec.

PTLA Stock Analysis - Frequently Asked Questions

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) posted its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.74) by $0.14. The biopharmaceutical company had revenue of $26.40 million for the quarter, compared to analysts' expectations of $33.88 million. Portola Pharmaceuticals had a negative trailing twelve-month return on equity of 267.86% and a negative net margin of 232.73%. The company's revenue was up 18.9% compared to the same quarter last year. During the same period last year, the business posted ($1.02) earnings per share.

What other stocks do shareholders of Portola Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Amarin (AMRN), Exelixis (EXEL), NVIDIA (NVDA), Geron (GERN), ACADIA Pharmaceuticals (ACAD) and Aileron Therapeutics (ALRN).

This page (NASDAQ:PTLA) was last updated on 5/19/2024 by Staff

From Our Partners